ADC Therapeutics SA, a leader in antibody drug conjugates, is set to release its quarterly earnings with an anticipated EPS of -$0.39 and revenue of $19 million.
The company will host a conference call and live webcast to discuss its financial results and provide operational updates.
Financial metrics show a mixed picture with a strong current ratio of 4.92 but concerns over profitability and debt levels.

ADC Therapeutics SA, listed on the NYSE as ADCT, is a prominent player in the field of antibody drug conjugates. These are targeted cancer therapies that combine antibodies with cytotoxic drugs. The company is set to release its quarterly earnings on March 27, 2025, with Wall Street estimating an earnings per share (EPS) of -$0.39 and projected revenue of $19 million.
On the same day, ADCT will host a conference call and live webcast at 8:30 a.m. EDT to discuss its financial results for the fourth quarter and the year ending December 31, 2024. This event will provide operational updates and is accessible via a toll-free number for North America and Canada, with a live webcast available on the company’s website.
ADCT’s financial metrics reveal a mixed picture. The company has a price-to-sales ratio of 2.21 and an enterprise value to sales ratio of 3.02, which are important indicators of how the market values its sales. However, the negative price-to-earnings ratio of -0.80 and earnings yield of -1.25% highlight its current lack of profitability.
Despite these challenges, ADCT maintains a strong current ratio of 4.92, indicating a solid ability to cover short-term liabilities. However, the enterprise value to operating cash flow ratio of -1.60 and a debt-to-equity ratio of -1.93 suggest a higher level of debt compared to equity, which could be a concern for investors.